Currently, three major categories of systemic treatment exist for the largest subgroup of mRCC, the clear cell carcinomas: cytokines and immune checkpoint inhibitors, anti VEGF targeted drugs and mTOR inhibitors [12]. The gene discussed is VEGFA; the disease is clear cell adenocarcinoma.